Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.
A popular diabetes and weight loss drug could be on the horizon in pill form as drugmaker Eli Lilly released results of an experimental GLP-1 phase three trial. Mounjaro, which is marketed to treat Type 2 diabetes, and Zepbound, which is intended to treat obesity, are used as injectable medications.
But a similar version of the drug, called orforglipron, could soon be administered in pill form, Eli Lilly said.The once-daily pill helped people lower their weight by an average of 12% after 72 weeks, which amounts to more than 27 pounds. The study involved more than 3,000 adults who had obesity or were overweight and had at least one weight-related health problem.The results have not yet been peer-reviewed.'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need,' said Ken Custer, executive vice president of Eli Lilly RELATED STORY | Deadline to stop selling cheaper, off-brand versions of GLP-1 medications nearsCurrent GLP-1 drugs to treat obesity and diabetes are injectable. Eli Lilly is among several companies trying to create a GLP-1 pill, but generally, these pills have more restrictions than injectable versions of the drug. Eli Lilly is hopeful the pills could be available as soon as this year.According to the Cleveland Clinic, these drugs help manage blood sugar levels by triggering insulin release from the pancreas. The drugs also help slow digestion, which causes less glucose to enter the bloodstream. The medicine also affects satiety, allowing patients to feel full after eating, the Cleveland Clinic said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly Foundation grants $5.5 million to Indianapolis Public Schools for STEM initiativeThe IPS Foundation has received a $5.5 million grant from the Eli Lilly Foundation to support Destination 2032, a new initiative aimed at enhancing STEM education for IPS students.
Read more »
Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli LillyPenn's Kiran Musunuru spoke with The Inquirer about the future of CRISPR technology.
Read more »
Penn sues Eli Lilly, CVS Caremark, and others over an insulin price schemeThere are hundreds of pending lawsuits against the drug companies and PBMs over insulin prices.
Read more »
Daily oral GLP-1 pill could be just as effective as weekly shots: DrugmakerEli Lilly announced Phase 3 trials results for its daily, oral GLP-1 drug.
Read more »
Eli Lilly shares drop after obesity pill shows modest late-stage trial resultsEli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs.
Read more »
Eli Lilly says new GLP-1 weight loss pill could reach market in 2026This is additional taxonomy that helps us with analytics
Read more »